Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 8/20 | 0.62 |
| ▸ | BRAF | P15056 | 17/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
| ▸ | FGR | P09769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721316 | 1.00 | NR1I2 (0.62) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL29721343 | 0.94 | BRAF (0.70) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL23458353 | 0.94 | BRAF (0.70) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL1127379 | 0.93 | NR1I2 (0.67) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL30659082 | 0.92 | NR1I2 (0.74) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL23458365 | 0.92 | NR1I2 (0.74) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL23458198 | 0.91 | NR1I2 (0.60) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL29721183 | 0.91 | NR1I2 (0.60) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL23458263 | 0.90 | NR1I2 (0.64) | NR1I2BRAFPLK4EPHB6RIPK2 | |
| SCHEMBL29721267 | 0.90 | NR1I2 (0.64) | NR1I2BRAFPLK4EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-02-02 | — | — | US | disclosed |
| EP-4069692-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021110997-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021110997-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036867-A1 | N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS | BRAF, RAF1, NRAS | NR1I2 2986/4885BRAF 1/4885PLK4 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.